Background Pilot studies indicate that probe-guided resectionof radioactive sentinel nodes (the first nodes that receivedrainage from tumors) can identify regional metastases in patientswith breast cancer. To confirm this finding, we conducted amulticenter study of the method as used by 11 surgeons in avariety of practice settings.
Methods We enrolled 443 patients with breast cancer. The techniqueinvolved the injection of 4 ml of technetium-99m sulfur colloid(1 mCi [37 MBq]) into the breast around the tumor or biopsycavity. "Hot spots" representing underlying sentinel nodes wereidentified with a gamma probe. Sentinel nodes subjacent to hotspots were removed. All patients underwent a complete axillarylymphadenectomy.
Results The overall rate of identification of hot spots was93 percent (in 413 of 443 patients). The pathological statusof the sentinel nodes was compared with that of the remainingaxillary nodes. The accuracy of the sentinel nodes with respectto the positive or negative status of the axillary nodes was97 percent (392 of 405); the specificity of the method was 100percent, the positive predictive value was 100 percent, thenegative predictive value was 96 percent (291 of 304), and thesensitivity was 89 percent (101 of 114). The sentinel nodeswere outside the axilla in 8 percent of cases and outside oflevel 1 nodes in 11 percent of cases. Three percent of positivesentinel nodes were in nonaxillary locations.
Conclusions Biopsy of sentinel nodes can predict the presenceor absence of axillary-node metastases in patients with breastcancer. However, the procedure can be technically challenging,and the success rate varies according to the surgeon and thecharacteristics of the patient.
The histologic status of axillary lymph nodes, one of the mostimportant prognostic indicators in patients with breast cancer,directly affects clinical management.1 However, over 80 percentof women who undergo axillary dissection have at least one postoperativecomplication in the arm, and psychological distress is common.2,3,4,5A potential alternative to axillary lymphadenectomy is sentinel-noderesection.
The first stop along the route of lymphatic drainage from aprimary tumor is a limited set of regional lymph nodes.6 Dyes,radiographic contrast agents, and radioactive tracers have beenused to identify such lymph nodes.7,8,9,10,11,12,13 More than20 years ago, Cabanas proposed that the lymph nodes that firstreceive drainage from a tumor, termed sentinel nodes, couldbe removed by limited surgery and examined to determine whethermore extensive lymphadenectomy should be performed.14 In 1992Morton et al. used a blue dye to identify the lymphatic ductthat drained into the sentinel nodes in patients with melanoma.15Alex and Krag described direct localization of sentinel nodeswith radioactive tracers and a hand-held gamma probe, demonstratingin an animal model that the radioactive-tracer and blue-dyemethods were equally effective in locating lymph nodes.16 Becausethe preliminary results with radioactive tracers were encouragingin patients with melanoma17,18 and patients with breast cancer,19,20we conducted a study in 11 centers to evaluate this method ofidentifying sentinel nodes in patients with breast cancer.
Methods
Patients
Patients were enrolled between May 1995 and September 1997 andgave informed consent. The protocol was approved by an institutionalreview committee at the University of Vermont and at each participatinginstitution. Participating surgeons were trained in the procedurein their own institutions by one of us. Each surgeon performedfive training procedures, the results of which are not partof the analysis. The target for each surgeon was 50 cases.
The inclusion criteria were the presence of invasive breastcancer, clinically negative results from examination of theipsilateral axilla, and a treatment plan that included axillarylymphadenectomy. The exclusion criteria were the presence ofclinically suspicious or overtly abnormal axillary nodes, pregnancy,previous axillary lymphadenectomy, or multiple primary breasttumors.
Radioactive Tracer
Thirty minutes to eight hours before surgery, 1 mCi (37 MBq)of technetium-99m sulfur colloid (CIS-US, Bedford, Mass.) ina volume of 4 ml was injected in divided aliquots at the 3-,6-, 9-, and 12-o'clock positions into the breast tissue surroundingthe primary tumor or biopsy cavity. Technetium-99m sulfur colloidwas prepared according to instructions on the package insert.A hand-held gamma counter (C-Trak, Care Wise Medical Products,Morgan Hill, Calif.) was then used to locate radioactive sentinelnodes. The surgeon first defined the perimeter of the radioactive-tracerdiffusion zone around the injection site, then examined thebreast and surrounding tissue for discrete regions of radioactivity.A "hot spot" was defined as an area of localized radioactivityseparate from the injection site with counts of at least 25per 10 seconds; the measurement was performed before the incisionwas made. Inability to identify a hot spot was considered atechnical failure, even if underlying radioactive sentinel nodeswere subsequently identified.
After all hot spots had been found, an appropriate incisionwas made for an axillary lymphadenectomy. Separate incisionswere made for sentinel nodes outside the axilla. Sentinel nodeswere identified by placing the gamma probe in the wound directlyunder the previously identified hot spot. The surgeon followedthe "line of sight" established by aiming the gamma probe towardthe site of maximal radioactivity emitted from the sentinelnodes and dissecting directly toward the sentinel nodes. Theradioactivity of each excised node was measured with a gammacounter. The radioactive nodes were removed until the backgroundradiation in the bed of the sentinel-node resection site wasless than 10 percent of that of the most radioactive resectedsentinel node.
A conventional lymphadenectomy including level I and II nodeswas then performed: level III nodes were removed if the surgeonconsidered them suspicious. Once removed, the lymphadenectomyspecimen was examined for radioactive nodes. Such nodes werenot considered sentinel nodes. For pathological examination,each sentinel node was processed separately, and the slideswere stained with hematoxylin and eosin. Deep sections and immunohistochemicalstains were not routinely employed.
Statistical Analysis
The rates of technical success for each surgeon and for allpatients are reported with exact 95 percent binomial confidenceintervals. Fisher's exact test for nominal variables and theWilcoxon rank-sum test for ordinal variables were used to comparethe rates of success according to the surgeon, the patient'sage and race, tumor size, location of the primary tumor, typeof tumor, method used to guide the injection, time from injectionto surgery, and type of previous biopsy. A forward variable-selectionmethod was used to examine these same variables in combinationwith 10 indicator variables representing the 11 surgeons todevelop multivariate logistic-regression models to predict technicalfailure. Potential predictors of technical failure were addedto the model if the likelihood-ratio chi-square statistic indicateda significant improvement (P<0.10) in predicting the observeddata. The Hosmer–Lemeshow goodness-of-fit criterion wasused to determine the adequacy of the final model.
For the comparison of the rates of false negative sentinel nodesand true positive sentinel nodes, we used Fisher's exact testand the Wilcoxon rank-sum test, as well as two-sample t-testsfor tumor size and total number of involved nodes. A Spearmanrank-correlation coefficient was used to examine the relationbetween the numbers of pathologically positive sentinel andnonsentinel nodes. Fisher's exact test was used to assess thedistribution of hot-spot locations, given the total number ofhot spots observed for each patient. We used SAS statisticalsoftware21 for data management and statistical analysis, StatXact322 to obtain 95 percent confidence intervals for technicalsuccess rates, and BMDP software23 to develop multivariate logistic-regressionmodels. All reported P values are two-tailed.
Results
Between May 1995 and September 1997, we enrolled 443 women inthe study. The mean (±SD) age of these patients was 56±12years, and 78 percent of them were white. The mean tumor sizewas 1.9±1.3 cm. The tumors were classified in terms ofsubtype as ductal (83.7 percent), lobular (8.6 percent), mixed(2.3 percent), or other (5.4 percent). The surgery performedwas mastectomy (in 31.4 percent of the women) or partial mastectomy(in 68.6 percent).
The mean interval between the injection of the radioactive tracerand surgery was 2.9±1.9 hours. On average, 18.9±6.9lymph nodes were removed from each patient, and the mean numberof sentinel nodes was 2.6±2.2. The overall rate of identificationof hot spots was 93.2 percent, but this value varied significantlyaccording to the surgeon (P=0.001) (Table 1). There was no significantunivariate relation between the successful identification ofa hot spot and the patient's age or race; the size, location,or histologic type of the tumor; the method of injecting thetracer; the interval between injection and surgery; or whetherthe patient had had a prior biopsy.
Table 1. Rate of Technical Success in Identifying a Hot Spot, According to Surgeon, before Incision.
On the basis of statistical modeling, which reflected a goodfit to the data (Hosmer–Lemeshow chi-square=7.5, 8 df;P=0.48), it appears that a prior excisional biopsy, an age of50 years or more, and a primary tumor in a medial location wereassociated with the failure to identify a hot spot (Table 2).These three factors were independent of variables related tothe techniques used by individual surgeons (Table 2).
Table 2. Results of the Logistic-Regression Model Predicting Failure to Identify a Hot Spot.
Among the 413 patients in whom one or more hot spots were identified,the hot spots were limited to one location in 92.7 percent,were in two locations in 6.8 percent, and were in three locationsin 0.5 percent of cases (Table 3). The distribution of hot spotsdiffered, depending on the number of hot spots identified (P=0.001).Overall, the 445 hot spots were found in level I (low axillary)nodes (in 89.0 percent of cases), internal mammary lymph nodes(4.3 percent), level II (midaxillary) nodes (4.0 percent), orother locations. Patients with two or more hot spots tendedto have more internal mammary hot spots and fewer level I hotspots than patients with only one hot spot. A sentinel nodewas not identified underneath the hot spot in 1.9 percent ofpatients (8 of 413).
Table 4 shows the pathological results for the 405 patientsin whom a sentinel node was resected. The observed sensitivityof the finding of a histologically positive sentinel node was88.6 percent (101 of 114); by definition, the specificity was100 percent. The observed accuracy of sentinel nodes for thedetection of metastatic disease was 96.8 percent (392 of 405);the positive predictive value was 100 percent (101 of 101),and the negative predictive value (i.e., the correlation ofnegative sentinel nodes with negative axillary nodes) was 95.7percent (291 of 304).
Table 4. Pathological Status of Sentinel Nodes and Nodes Obtained by Axillary Lymphadenectomy.
The false negative rate did not vary significantly among thesurgeons (Table 5). There were too few false negative results(13) for extensive comparison with true positive results (101)in terms of variables that may have affected the likelihoodof a false negative result. Univariate analysis indicated thatall 13 false negative results occurred when the primary tumorwas in the lateral half of the breast (P=0.004). None of theother variables tested were statistically associated with afalse negative result.
Table 5. Sentinel-Node False Negative Rate According to Surgeon.
There was a significant correlation between the number of pathologicallypositive sentinel nodes and the number of positive nonsentinelnodes obtained at axillary lymphadenectomy (Spearman's rank-correlationcoefficient, 0.49; P<0.001) (Table 6). Among 304 patientswith no positive sentinel nodes, 4.3 percent had nonsentinelnodes that were pathologically positive. Among 95 patients withone to three positive sentinel nodes, 37.9 percent had positivenonsentinel nodes. Among six patients with four or more positivesentinel nodes, 83.3 percent had positive nonsentinel nodes.
Table 6. Relation between Pathologically Positive Sentinel Nodes and Pathologically Positive Nonsentinel Nodes.
Discussion
In this study of a method of identifying sentinel lymph nodesin women with breast cancer by means of a locally injected radioactivecolloid, we found localized radioactivity (hot spots), presumablyrepresenting sentinel nodes, in 93.2 percent of cases. Therewas, however, considerable variation in the rate of successin detecting such nodes among the participating surgeons, evenafter each had performed five training procedures. Before thismethod can be broadly applied in clinical practice, technicalimprovements in identifying sentinel nodes will be necessary.
Injections of the radioactive colloid were more widely spacedaround a prior biopsy cavity than around a primary tumor. Thedeposition of insufficient amounts of colloid between injectionsites may explain why a previous excisional biopsy reduces theprobability of finding a hot spot. Perhaps excisional biopsyshould be avoided if a search for sentinel nodes is planned.
The patient's age and the location of the primary tumor affectedthe success rate of the method we used. In older patients thecapacity of lymph nodes to retain the radioactive colloid maybe decreased, because lymph nodes are replaced by fat in elderlypersons. Increasing the volume of the diluent and the amountof tracer can increase its uptake by sentinel nodes by a factorof 10 and may offset this problem (unpublished data). The relativelyhigh rate of failure to identify sentinel nodes in medial tumorsis probably related to overshadowing (masking) of internal mammarynodes by the injection site.
Among the 405 patients with sentinel nodes, the accuracy ofthe sentinel nodes (the number of cases in which the pathologicalstatus of the sentinel nodes corresponded to the pathologicalstatus of the axillary nodes, divided by the number of cases)was 97 percent. Whereas the positive predictive value was 100percent by definition, the negative predictive value was alsovery good, at 96 percent. These results appear to support, atleast in part, the hypothesis that the status of the sentinelnode can accurately predict whether nodal metastases are present.However, the sensitivity was 89 percent, and the false negativerate for this study was 11 percent.
After injection, the tracer diffuses, resulting in a variablearea of radioactivity with a diameter of several centimeters.Probe counts over this diffusion zone are generally much higherthan those over sentinel nodes. Sentinel nodes located awayfrom the injection site were readily located, because backgroundcounts around the sentinel nodes were low. By contrast, sentinelnodes located near or within the zone of diffusion were notreadily identified, because background counts could exceed thecounts for the sentinel nodes. These two situations highlightthe strengths and pitfalls of probe-guided resection of sentinelnodes: the farther the sentinel nodes are from the tumor, themore readily they are identified, whereas the closer the sentinelnodes are to the tumor, the more difficult they are to identify.
All false negative results occurred when the primary tumor wasin the lateral half of the breast. The control resection wasan axillary lymphadenectomy. To fully test the false negativerate would require a control resection of all possible drainagebasins (internal mammary, infraclavicular, and supraclavicular),which is not feasible. With tumors closer to the potential lymph-nodebasin, technical problems occurred. In the case of a lesionin the lateral half of the breast that drained only to loweraxillary nodes, with at least one cancer-containing sentinelnode that was missed by the probe, a false negative result wouldbe recorded. For this reason, an improved sentinel-node proceduremay not be successful in all patients with breast cancer, evenwith technical modifications. Increasing the volume of tracerinjected can increase the rate of successful identificationof sentinel nodes to 100 percent, according to a report fromone institution.20 Increased volume, which increases the countrate of sentinel nodes (unpublished data), makes the nodes morereadily apparent and should lower the false negative rate whenthe lesion is in the lateral half of the breast. Vital dyesthat provide a visual aid24,25,26 may be complementary to probe-guidedsurgery and lower the false negative rate.
This study may underestimate the number of cases in which primarylymphatic drainage occurs outside the axilla. By using locallyinjected radioactive colloids, Hultborn et al. found a highrate of nonaxillary drainage in patients with breast cancer.27In a study of 250 women without pathologic changes in the breast,there was primary lymphatic drainage to the internal mammarynodes in 20 percent to 86 percent of cases, depending on thequadrant injected.28 Nonaxillary drainage is clinically relevant,because metastases that are exclusive to internal mammary nodesoccur in 5 percent to 10 percent of women with breast cancer.The prognosis is the same for these women as for those withaxillary metastases.29 An autopsy study reported that 90 percentof women who died of breast cancer had metastases in the internalmammary nodes.30 Moreover, a first pleural effusion from breastcancer occurs more frequently on the same side as the breastcancer, suggesting regional thoracic involvement through theinternal mammary nodes.31,32 Probe guidance virtually eliminatesthe morbidity associated with resection of internal mammarynodes and hence may improve the accuracy of node staging byextending the procedure to patients with nonaxillary sentinelnodes.
With probe-guided surgery and the use of colloidal albumin (Nanocoll,Sorin Biomedica, Saluggia, Italy) injected into the parenchyma33or subdermis26 of the breast, the rates of sentinel-node identificationwere 94 percent and 98 percent, and the false negative rateswere 2.3 percent and 4.7 percent, respectively. With blue dyealone injected into the parenchyma of the breast, rates of sentinel-nodeidentification ranged from 65 percent to 93 percent, and falsenegative rates from 0 to 12 percent.25,34
Our reasons for requiring that sentinel nodes be located beforethe incision was made were to document the success rates ofindividual surgeons, allow optimal placement of the incision,and allow accurate targeting in the axillary and nonaxillarynodes. In 3 percent of cases with positive nodes, only nonaxillarysentinel nodes were positive. Removal of nonaxillary nodes hasnot been reported by other investigators. When only blue dyeis used, the incision begins over level I nodes and continuesuntil a blue-stained lymphatic duct is identified. With bluedye, the location of the incision is always the same; however,the location of axillary sentinel lymph nodes varies. To theextent that the location of the nodes varies, so will the amountof dissection. Sentinel nodes that are not in the axilla arenot identified with blue dye.
The completeness of resection of the sentinel nodes was rapidlyconfirmed by placing the gamma detector back into the woundafter removal of the initial sentinel node. When only blue dyewas used, the method of establishing whether multiple sentinelnodes were present was additional random dissection, of whichthe end point is not clear.
On the basis of the results of this study, we conclude thatit is feasible to perform the sentinel-node procedure successfullyin a variety of surgical settings. The procedure can be technicallychallenging, as indicated by the fact that the success ratevaried among surgeons and according to the patients' characteristics.Since the study began in 1995, modifications of the technique,such as increasing the volume of tracer injected, have improvedthe uptake of tracer by the sentinel nodes. Other investigators,using a variety of techniques, have also had good results, andcombining complementary methods may further improve the technicalability to identify all draining sentinel nodes.
Pathological examination of the sentinel nodes revealed thattheir status accurately predicts the status of the axillarynodes. In particular, examination of the sentinel nodes hasgood negative predictive value. However, false negative resultswere observed in the case of lesions located in the lateralhalf of the breast, probably because of the closeness of theinjection site to the underlying sentinel nodes.
By using radioactive tracers, we could identify clinically relevantsentinel nodes outside the axilla; these would have been missedby a conventional axillary lymphadenectomy, since 3 percentof all patients with positive nodes in this series had positivenodes only outside the axilla. On the basis of these results,it is overly simplistic to name a single location as the repositoryof all lymphatic metastases from a primary breast cancer.
Supported by grants (U01 CA65121-02 and P30CA22435) from theNational Cancer Institute.
We are indebted to Ms. Elizabeth Joyce, M.P.A., clinical researchsupervisor; to Ms. Mary Krupski, B.A., research data specialist;and to Mr. Robert Bolyard, records coordinator — all atthe Vermont Cancer Center.
Source Information
From the Cancer Center (D.K.) and the Departments of Surgery (D.K., S.H.), Pathology (D.W.), and Biometry (T.A.), University of Vermont, Burlington; the Sylvester Cancer Center, Miami (F.M.); the Arkansas Cancer Research Center, Little Rock (V.S.K.); Walter Reed Army Medical Center, Washington, D.C. (C.S.); Benedictine Hospital, Kingston, N.Y. (S.F.); Charleston Area Medical Center, Charleston, W.V. (R.K.); Massachusetts General Hospital, Boston (M.G.); Baylor University Medical Center, Dallas (J.K.); and St. Paul Hospital, Dallas (P.B.). Other authors were Pat Whitworth, Jr., M.D., Nashville Surgical Associates, Nashville; Roger Foster, Jr., M.D., Crawford Long Hospital, Emory University, Atlanta; and Kambiz Dowlatshahi, M.D., Rush–Presbyterian–St. Luke's Medical Center, Chicago.The views expressed in this article are solely those of the authors and do not necessarily represent the official views of the National Cancer Institute, the federal government, or the Department of Defense.
Address reprint requests to Dr. Krag at Given Bldg. E309, University of Vermont, Burlington, VT 05405.
References
Breast. In: Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott–Raven, 1997:171-80.
Assa J. The intercostobrachial nerve in radical mastectomy. J Surg Oncol 1974;6:123-126. [CrossRef][Medline]
Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:1575-1582. [Medline]
Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg 1993;36:315-320. [Medline]
Hladiuk M, Huchcroft S, Temple W, Schnurr BE. Arm function after axillary dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Oncol 1992;50:47-52. [Medline]
Braithwaite LR. The flow of lymph from the ileocaecal angle, and its possible bearing on the cause of duodenal and gastric ulcer. Br J Surg 1923;11:7-26. [CrossRef]
Gray JH. Relation of lymphatic vessels to the spread of cancer. Br J Surg 1939;26:462-495. [CrossRef]
Weinberg J, Greaney EM. Identification of regional lymph nodes by means of a vital staining dye during surgery of gastric cancer. Surg Gynecol Obstet 1950;90:561-567. [Medline]
Weinberg JA. Identification of regional lymph nodes in the treatment of bronchiogenic carcinoma. J Thorac Surg 1951;22:517-26.
Busch RM, Sayegh ES. Roentgenographic visualization of human testicular lymphatics: a preliminary report. J Urol 1963;89:106-110. [Medline]
Chiappa S, Galli G, Barbaini S, Ravasi G, Bagliani G. La lymphographic peroperatoire dans les tumeurs du testicule. J Radiol Electr 1963;44:613.
Chiappa S, Uslenghi C, Bonadonna G, Marano P, Ravasi G. Combined testicular and foot lymphangiography in testicular carcinomas. Surg Gynecol Obstet 1966;123:10-14. [Medline]
Sayegh E, Brooks T, Sacher E, Busch F. Lymphangiography of the retroperitoneal lymph nodes through the inguinal route. J Urol 1966;95:102-107. [Medline]
Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-466. [CrossRef][Medline]
Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399. [Free Full Text]
Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg Oncol 1993;2:137-143. [CrossRef][Medline]
Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-658. [Free Full Text]
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-339. [CrossRef][Medline]
Krag DN, Ashikaga T, Harlow SP, Weaver DL. Development of sentinel node targeting technique in breast cancer patients. Breast 1998;4(2):67-74.
SAS/STAT user's guide, version 6. 4th ed. Vol. 1. Cary, N.C.: SAS Institute, 1989 (software).
StatXact for Windows. Cambridge, Mass.: CYTEL Software, 1995 (software).
Dixon WJ, ed. BMDP statistical software manual. Vol. 2. Berkeley: University of California Press, 1992 (software).
Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph-node in breast cancer. Lancet 1997;349:1668-1669. [Medline]
Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-398. [Medline]
Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymphnodes. Lancet 1997;349:1864-1867. [CrossRef][Medline]
Hultborn KA, Larsson L-G, Ragnhult I. The lymph drainage from the breast to the axillary and parasternal lymph nodes, studied with the aid of colloidal AU198. Acta Radiol 1955;43:52-64.
Vendrell-Torne E, Setoain-Quinquer J, Domenech-Torne FM. Study of normal mammary lymphatic drainage using radioactive isotopes. J Nucl Med 1972;13:801-805. [Free Full Text]
Morrow M, Foster RS Jr. Staging of breast cancer: a new rationale for internal mammary node biopsy. Arch Surg 1981;116:748-751. [Free Full Text]
Thomas JM, Redding WH, Sloane JP. The spread of breast cancer: importance of the intrathoracic lymphatic route and its relevance to treatment. Br J Cancer 1979;40:540-547. [Medline]
Porter EH. Pleural effusion and breast cancer. BMJ 1965;5429:251-252.
Stoll BA, Ellis F. Treatment by oestrogens of pulmonary metastases from breast cancer. BMJ 1953;2:796-800. [Medline]
Pijpers R, Meijer S, Hoekstra OS, et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nucl Med 1997;38:366-368. [Free Full Text]
Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-2350. [Free Full Text]
Sentinel-Lymph-Node Biopsy
Schillaci O., Scopinaro F., Abramson L. R., Retsas S., Krag D. N., Moffat F. L., Ashikaga T., McMasters K. M., Edwards M. J., Ross M. I.
Extract |
Full Text
N Engl J Med 1999;
340:317-319, Jan 28, 1999.
Correspondence
This article has been cited by other articles:
Krag, D. N., Ashikaga, T., Harlow, S. P., Skelly, J. M., Julian, T. B., Brown, A. M., Weaver, D. L., Wolmark, N., for the National Surgical Adjuvant Breast and Bowe,
(2009). Surgeon Training, Protocol Compliance, and Technical Outcomes From Breast Cancer Sentinel Lymph Node Randomized Trial. JNCI J Natl Cancer Inst
101: 1356-1362
[Abstract][Full Text]
Dabakuyo, T. S., Fraisse, J., Causeret, S., Gouy, S., Padeano, M.-M., Loustalot, C., Cuisenier, J., Sauzedde, J.-M., Smail, M., Combier, J.-P., Chevillote, P., Rosburger, C., Boulet, S., Arveux, P., Bonnetain, F.
(2009). A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection. Ann Oncol
20: 1352-1361
[Abstract][Full Text]
Zivanovic, O., Khoury-Collado, F., Abu-Rustum, N. R., Gemignani, M. L.
(2009). Sentinel Lymph Node Biopsy in the Management of Vulvar Carcinoma, Cervical Cancer, and Endometrial Cancer. The Oncologist
14: 695-705
[Abstract][Full Text]
Spillane, A. J., Noushi, F., Cooper, R. A., Gebski, V., Uren, R. F.
(2009). High-resolution lymphoscintigraphy is essential for recognition of the significance of internal mammary nodes in breast cancer. Ann Oncol
20: 977-984
[Abstract][Full Text]
Canavese, G., Catturich, A., Vecchio, C., Tomei, D., Gipponi, M., Villa, G., Carli, F., Bruzzi, P., Dozin, B.
(2009). Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol
20: 1001-1007
[Abstract][Full Text]
Chae, B. J., Bae, J. S., Kang, B. J., Kim, S. H., Jung, S. S., Song, B. J.
(2009). Positron Emission Tomography-Computed Tomography in the Detection of Axillary Lymph Node Metastasis in Patients with Early Stage Breast Cancer. Jpn J Clin Oncol
39: 284-289
[Abstract][Full Text]
McCahill, L. E., Privette, A., James, T., Sheehey-Jones, J., Ratliff, J., Majercik, D., Krag, D. N., Stanley, M., Harlow, S.
(2009). Quality Measures for Breast Cancer Surgery: Initial Validation of Feasibility and Assessment of Variation Among Surgeons. Arch Surg
144: 455-462
[Abstract][Full Text]
Abe, H., Schmidt, R. A., Kulkarni, K., Sennett, C. A., Mueller, J. S., Newstead, G. M.
(2009). Axillary Lymph Nodes Suspicious for Breast Cancer Metastasis: Sampling with US-guided 14-Gauge Core-Needle Biopsy--Clinical Experience in 100 Patients. Radiology
250: 41-49
[Abstract][Full Text]
van Deurzen, C H M, Borgstein, P J, van Diest, P J
(2008). In-transit lymph node metastases in breast cancer: a possible source of local recurrence after Sentinel Node procedure. J. Clin. Pathol.
61: 1314-1316
[Abstract][Full Text]
Poletti, P., Fenaroli, P., Milesi, A., Paludetti, A., Mangiarotti, S., Virotta, G., Candiago, E., Bettini, A., Caremoli, E. R., Labianca, R., Tondini, C.
(2008). Axillary recurrence in sentinel lymph node-negative breast cancer patients. Ann Oncol
19: 1842-1846
[Abstract][Full Text]
Grube, B. J., Christy, C. J., Black, D., Martel, M., Harris, L., Weidhaas, J., DiGiovanna, M. P., Chung, G., Abu-Khalaf, M. M., Miller, K. D., Higgins, S. A., Philpotts, L., Tavassoli, F. A., Lannin, D. R.
(2008). Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy. Arch Surg
143: 692-700
[Abstract][Full Text]
Edge, S. B.
(2008). Early Adoption and Disturbing Disparities in Sentinel Node Biopsy in Breast Cancer. JNCI J Natl Cancer Inst
100: 449-450
[Full Text]
Sevick-Muraca, E. M., Sharma, R., Rasmussen, J. C., Marshall, M. V., Wendt, J. A., Pham, H. Q., Bonefas, E., Houston, J. P., Sampath, L., Adams, K. E., Blanchard, D. K., Fisher, R. E., Chiang, S. B., Elledge, R., Mawad, M. E.
(2008). Imaging of Lymph Flow in Breast Cancer Patients after Microdose Administration of a Near-Infrared Fluorophore: Feasibility Study. Radiology
246: 734-741
[Abstract][Full Text]
MINIGH, J.
(2008). Sentinel Lymph Node Mapping of the Breast. radtech
79: 243M-257M
[Abstract][Full Text]
Teixeira Soares, C., Frederigue-Junior, U., de Luca, L. A.
(2007). Anatomopathological Analysis of Sentinel and Nonsentinel Lymph Nodes in Breast Cancer: Hematoxylin-Eosin Versus Immunohistochemistry. INT J SURG PATHOL
15: 358-368
[Abstract]
Abe, H., Schmidt, R. A., Sennett, C. A., Shimauchi, A., Newstead, G. M.
(2007). US-guided Core Needle Biopsy of Axillary Lymph Nodes in Patients with Breast Cancer: Why and How to Do It. RadioGraphics
27: S91-S99
[Abstract][Full Text]
Abba, M. C., Sun, H., Hawkins, K. A., Drake, J. A., Hu, Y., Nunez, M. I., Gaddis, S., Shi, T., Horvath, S., Sahin, A., Aldaz, C. M.
(2007). Breast Cancer Molecular Signatures as Determined by SAGE: Correlation with Lymph Node Status. Mol Cancer Res
5: 881-890
[Abstract][Full Text]
Bourgeois, P.
(2007). Scintigraphic Investigations of the Lymphatic System: The Influence of Injected Volume and Quantity of Labeled Colloidal Tracer. JNM
48: 693-695
[Abstract][Full Text]
Blancas, I, Garcia-Puche, J., Bermejo, B, Hanrahan, E., Monteagudo, C, Martinez-Agullo, A, Rouzier, R, Hennessy, B., Valero, V, Lluch, A
(2006). Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor. Ann Oncol
17: 1644-1649
[Abstract][Full Text]
Chen, S. L., Iddings, D. M., Scheri, R. P., Bilchik, A. J.
(2006). Lymphatic Mapping and Sentinel Node Analysis: Current Concepts and Applications. CA Cancer J Clin
56: 292-309
[Abstract][Full Text]
Knauer, M., Konstantiniuk, P., Haid, A., Wenzl, E., Riegler-Keil, M., Postlberger, S., Reitsamer, R., Schrenk, P.
(2006). Multicentric Breast Cancer: A New Indication for Sentinel Node Biopsy--A Multi-Institutional Validation Study. JCO
24: 3374-3380
[Abstract][Full Text]
Pandit-Taskar, N., Dauer, L. T., Montgomery, L., St. Germain, J., Zanzonico, P. B., Divgi, C. R.
(2006). Organ and Fetal Absorbed Dose Estimates from 99mTc-Sulfur Colloid Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer Patients. JNM
47: 1202-1208
[Abstract][Full Text]
Sachelarie, I., Grossbard, M. L., Chadha, M., Feldman, S., Ghesani, M., Blum, R. H.
(2006). Primary Systemic Therapy of Breast Cancer. The Oncologist
11: 574-589
[Abstract][Full Text]
Bleiweiss, I. J., Nagi, C. S., Jaffer, S.
(2006). Axillary Sentinel Lymph Nodes Can Be Falsely Positive Due to Iatrogenic Displacement and Transport of Benign Epithelial Cells in Patients With Breast Carcinoma. JCO
24: 2013-2018
[Abstract][Full Text]
Houvenaeghel, G., Nos, C., Mignotte, H., Classe, J. M., Giard, S., Rouanet, P., Lorca, F. P., Jacquemier, J., Bardou, V. J.
(2006). Micrometastases in Sentinel Lymph Node in a Multicentric Study: Predictive Factors of Nonsentinel Lymph Node Involvement--Groupe Des Chirurgiens De La Federation Des Centres De Lutte Contre Le Cancer. JCO
24: 1814-1822
[Abstract][Full Text]
Newman, L. A.
(2005). Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer Patients. J Oncol Pract
1: 130-133
[Full Text]
Pandit-Taskar, N.
(2005). Oncologic Imaging in Gynecologic Malignancies. JNM
46: 1842-1850
[Abstract][Full Text]
Lyman, G. H., Giuliano, A. E., Somerfield, M. R., Benson, A. B. III, Bodurka, D. C., Burstein, H. J., Cochran, A. J., Cody, H. S. III, Edge, S. B., Galper, S., Hayman, J. A., Kim, T. Y., Perkins, C. L., Podoloff, D. A., Sivasubramaniam, V. H., Turner, R. R., Wahl, R., Weaver, D. L., Wolff, A. C., Winer, E. P.
(2005). American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. JCO
23: 7703-7720
[Abstract][Full Text]
Kluger, H. M., Chelouche Lev, D., Kluger, Y., McCarthy, M. M., Kiriakova, G., Camp, R. L., Rimm, D. L., Price, J. E.
(2005). Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease. Cancer Res.
65: 5578-5587
[Abstract][Full Text]
Mamounas, E. P., Brown, A., Anderson, S., Smith, R., Julian, T., Miller, B., Bear, H. D., Caldwell, C. B., Walker, A. P., Mikkelson, W. M., Stauffer, J. S., Robidoux, A., Theoret, H., Sovan, A., Fisher, B., Wickerham, D. L., Wolmark, N.
(2005). Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27. JCO
23: 2694-2702
[Abstract][Full Text]
Classe, J.-M., Fiche, M., Rousseau, C., Sagan, C., Dravet, F., Pioud, R., Lisbona, A., Ferrer, L., Campion, L., Resche, I., Curtet, C.
(2005). Prospective Comparison of 3 {gamma}-Probes for Sentinel Lymph Node Detection in 200 Breast Cancer Patients. JNM
46: 395-399
[Abstract][Full Text]
Luini, A., Gatti, G., Ballardini, B., Zurrida, S., Galimberti, V., Veronesi, P., Vento, A. R., Monti, S., Viale, G., Paganelli, G., Veronesi, U.
(2005). Development of axillary surgery in breast cancer. Ann Oncol
16: 259-262
[Abstract][Full Text]
Tiffet, O., Nicholson, A. G., Khaddage, A., Prevot, N., Ladas, G., Dubois, F., Goldstraw, P.
(2005). Feasibility of the Detection of the Sentinel Lymph Node in Peripheral Non-small Cell Lung Cancer With Radio Isotopic and Blue Dye Techniques. Chest
127: 443-448
[Abstract][Full Text]
Santamaria, G., Velasco, M., Farre, X., Vanrell, J. A., Cardesa, A., Fernandez, P. L.
(2005). Power Doppler Sonography of Invasive Breast Carcinoma: Does Tumor Vascularization Contribute to Prediction of Axillary Status?. Radiology
234: 374-380
[Abstract][Full Text]
Dan, A. G., Saha, S., Monson, K. M., Wiese, D., Schochet, E., Barber, K. R., Ganatra, B., Desai, D., Kaushal, S.
(2004). 1% Lymphazurin vs 10% Fluorescein for Sentinel Node Mapping in Colorectal Tumors. Arch Surg
139: 1180-1184
[Abstract][Full Text]
Lamichhane, N, Shen, K W, Li, C L, Han, Q X, Zhang, Y J, Shao, Z M, Shen, Z Z
(2004). Sentinel lymph node biopsy in breast cancer patients after overnight migration of radiolabelled sulphur colloid. Postgrad. Med. J.
80: 546-550
[Abstract][Full Text]
Jung, J. I., Kim, H. H., Park, S. H., Song, S. W., Chung, M. H., Kim, H. S., Kim, K. J., Ahn, M. I., Seo, S. B., Hahn, S. T.
(2004). Thoracic Manifestations of Breast Cancer and Its Therapy. RadioGraphics
24: 1269-1285
[Abstract][Full Text]
Glinsky, G. V., Higashiyama, T., Glinskii, A. B.
(2004). Classification of Human Breast Cancer Using Gene Expression Profiling as a Component of the Survival Predictor Algorithm. Clin. Cancer Res.
10: 2272-2283
[Abstract][Full Text]
Wahl, R. L., Siegel, B. A., Coleman, R. E., Gatsonis, C. G.
(2004). Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group. JCO
22: 277-285
[Abstract][Full Text]
Louis-Sylvestre, C., Clough, K., Asselain, B., Vilcoq, J. R., Salmon, R. J., Campana, F., Fourquet, A.
(2004). Axillary Treatment in Conservative Management of Operable Breast Cancer: Dissection or Radiotherapy? Results of a Randomized Study With 15 Years of Follow-Up. JCO
22: 97-101
[Abstract][Full Text]
Mamounas, E. P.
(2003). NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions. Clin Med Res
1: 309-326
[Abstract][Full Text]
Krynyckyi, B. R., Chun, H., Kim, H. H., Eskandar, Y., Kim, C. K., Machac, J.
(2003). Factors Affecting Visualization Rates of Internal Mammary Sentinel Nodes During Lymphoscintigraphy. JNM
44: 1387-1393
[Abstract][Full Text]
Veronesi, U., Paganelli, G., Viale, G., Luini, A., Zurrida, S., Galimberti, V., Intra, M., Veronesi, P., Robertson, C., Maisonneuve, P., Renne, G., De Cicco, C., De Lucia, F., Gennari, R.
(2003). A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer. NEJM
349: 546-553
[Abstract][Full Text]
Blanchard, D. K., Donohue, J. H., Reynolds, C., Grant, C. S.
(2003). Relapse and Morbidity in Patients Undergoing Sentinel Lymph Node Biopsy Alone or With Axillary Dissection for Breast Cancer. Arch Surg
138: 482-488
[Abstract][Full Text]
Koizumi, M., Makita, M., Yoshimoto, M., Kasumi, F., Sakamoto, G., Ogata, E.
(2002). Indications for Sentinel Lymph Node Biopsy in Patients with Breast Cancer: Retrospective and Simulation Analyses. Jpn J Clin Oncol
32: 517-524
[Abstract][Full Text]
Sato, K., Tamaki, K., Shigekawa, T., Tsuda, H., Kosuda, S., Kusano, S., Hiraide, H., Mochizuki, H.
(2002). Clinically Useful Detection Criteria for Sentinel Nodes in Patients with Breast Cancer Using a Radioisotope Technique. Jpn J Clin Oncol
32: 403-406
[Abstract][Full Text]
Bonnema, J., van de Velde, C. J. H.
(2002). Sentinel lymph node biopsy in breast cancer. Ann Oncol
13: 1531-1537
[Abstract][Full Text]
Schmidt, F. E., Woltering, E. A., Webb, W. R., Garcia, O. M., Cohen, J. E., Rozans, M. H.
(2002). Sentinel nodal assessment in patients with carcinoma of the lung. Ann. Thorac. Surg.
74: 870-875
[Abstract][Full Text]
Morrow, M., Strom, E. A., Bassett, L. W., Dershaw, D. D., Fowble, B., Giuliano, A., Harris, J. R., O'Malley, F., Schnitt, S. J., Singletary, S. E., Winchester, D. P.
(2002). Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma. CA Cancer J Clin
52: 277-300
[Abstract][Full Text]
Chen, M., Palleschi, S., Khoynezhad, A., Gecelter, G., Marini, C. P., Simms, H. H.
(2002). Role of Primary Breast Cancer Characteristics in Predicting Positive Sentinel Lymph Node Biopsy Results: A Multivariate Analysis. Arch Surg
137: 606-610
[Abstract][Full Text]
Weir, L., Speers, C., D'yachkova, Y., Olivotto, I. A.
(2002). Prognostic Significance of the Number of Axillary Lymph Nodes Removed in Patients With Node-Negative Breast Cancer. JCO
20: 1793-1799
[Abstract][Full Text]
Vallejo Mar, M., Gee-Johnson, S., Kim, E. E., Podoloff, D. A.
(2002). Whole-Body Lymphoscintigraphy Using Transmission Scans. J. Nucl. Med. Technol.
30: 12-17
[Abstract][Full Text]
Morrow, M., Gradishar, W.
(2002). Recent developments: Breast cancer. BMJ
324: 410-414
[Full Text]
Goessling, W., McKee, P. H., Mayer, R. J.
(2002). Merkel Cell Carcinoma. JCO
20: 588-598
[Full Text]
Liberman, L., Cody, H. S. III
(2001). Percutaneous Biopsy and Sentinel Lymphadenectomy: Minimally Invasive Diagnosis and Treatment of Nonpalpable Breast Cancer. Am. J. Roentgenol.
177: 887-891
[Abstract][Full Text]
Ell, P J
(2001). A revolution in surgical oncology: sentinel lymph node biopsy. Imaging
13: 197-205
[Abstract][Full Text]
Rahusen, F. D., Torrenga, H., van Diest, P. J., Pijpers, R., van der Wall, E., Licht, J., Meijer, S.
(2001). Predictive Factors for Metastatic Involvement of Nonsentinel Nodes in Patients With Breast Cancer. Arch Surg
136: 1059-1063
[Abstract][Full Text]
Yang, W. T., Metreweli, C., Lam, P. K. W., Chang, J.
(2001). Benign and Malignant Breast Masses and Axillary Nodes: Evaluation with Echo-enhanced Color Power Doppler US. Radiology
220: 795-802
[Abstract][Full Text]
Mariani, G., Moresco, L., Viale, G., Villa, G., Bagnasco, M., Canavese, G., Buscombe, J., Strauss, H. W., Paganelli, G.
(2001). Radioguided Sentinel Lymph Node Biopsy in Breast Cancer Surgery. JNM
42: 1198-1215
[Abstract][Full Text]
Sato, K., Tamaki, K., Takeuchi, H., Tsuda, H., Kosuda, S., Kusano, S., Hiraide, H., Mochizuki, H.
(2001). Management of the Axilla in Breast Cancer: a Comparative Study Between Sentinel Lymph Node Biopsy and Four-node Sampling Procedure. Jpn J Clin Oncol
31: 318-321
[Abstract][Full Text]
Cantin, J., Scarth, H., Levine, M., Hugi, M.
(2001). Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy. CMAJ
165: 166-173
[Abstract][Full Text]
Mincey, B. A., Bammer, T., Atkinson, E. J., Perez, E. A.
(2001). Role of Axillary Node Dissection in Patients With T1a and T1b Breast Cancer: Mayo Clinic Experience. Arch Surg
136: 779-782
[Abstract][Full Text]
Torrenga, H, Rahusen, F D, Meijer, S, Borgstein, P J, van Diest, P J
(2001). Sentinel node investigation in breast cancer: detailed analysis of the yield from step sectioning and immunohistochemistry. J. Clin. Pathol.
54: 550-552
[Abstract][Full Text]
Birdwell, R. L., Smith, K. L., Betts, B. J., Ikeda, D. M., Strauss, H. W., Jeffrey, S. S.
(2001). Breast Cancer: Variables Affecting Sentinel Lymph Node Visualization at Preoperative Lymphoscintigraphy. Radiology
220: 47-53
[Abstract][Full Text]
Vera, D. R., Wallace, A. M., Hoh, C. K., Mattrey, R. F.
(2001). A Synthetic Macromolecule for Sentinel Node Detection: 99mTc-DTPA-Mannosyl-Dextran. JNM
42: 951-959
[Abstract][Full Text]
Wong, S. L., Edwards, M. J., Chao, C., Tuttle, T. M., Noyes, R. D., Woo, C., Cerrito, P. B., McMasters, K. M., for the University of Louisville Breast Cancer Sen,
(2001). Predicting the Status of the Nonsentinel Axillary Nodes: A Multicenter Study. Arch Surg
136: 563-568
[Abstract][Full Text]
Greco, M., Crippa, F., Agresti, R., Seregni, E., Gerali, A., Giovanazzi, R., Micheli, A., Asero, S., Ferraris, C., Gennaro, M., Bombardieri, E., Cascinelli, N.
(2001). Axillary Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-D-glucose-Positron Emission Tomography: Clinical Evaluation and Alternative Management. JNCI J Natl Cancer Inst
93: 630-635
[Abstract][Full Text]
Yeung, H. W.D., Cody III, H. S., Turlakow, A., Riedel, E. R., Fey, J., Gonen, M., Nuñez, R., Yeh, S. D., Larson, S. M.
(2001). Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer Patients: A Comparison Between 1-Day and 2-Day Protocols. JNM
42: 420-423
[Abstract][Full Text]
Ravdin, P. M., Siminoff, L. A., Davis, G. J., Mercer, M. B., Hewlett, J., Gerson, N., Parker, H. L.
(2001). Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer. JCO
19: 980-991
[Abstract][Full Text]
Tuthill, L. L., Reynolds, H. E., Goulet, R. J. Jr.
(2001). Biopsy of Sentinel Lymph Nodes Guided by Lymphoscintigraphic Mapping in Patients with Breast Cancer. Am. J. Roentgenol.
176: 407-411
[Abstract][Full Text]
Breslin, T. M., Cohen, L., Sahin, A., Fleming, J. B., Kuerer, H. M., Newman, L. A., Delpassand, E. S., House, R., Ames, F. C., Feig, B. W., Ross, M. I., Singletary, S. E., Buzdar, A. U., Hortobagyi, G. N., Hunt, K. K.
(2000). Sentinel Lymph Node Biopsy Is Accurate After Neoadjuvant Chemotherapy for Breast Cancer. JCO
18: 3480-3486
[Abstract][Full Text]
Haigh, P. I., Hansen, N. M., Giuliano, A. E., Edwards, G. K., Ye, W., Glass, E. C.
(2000). Factors Affecting Sentinel Node Localization During Preoperative Breast Lymphoscintigraphy. JNM
41: 1682-1688
[Abstract][Full Text]
Cserni, G
(2000). Axillary staging of breast cancer and the sentinel node. J. Clin. Pathol.
53: 733-741
[Abstract][Full Text]
Guenther, J. M., Collins, J. C., Barnes, G. Jr, O'Connell, T. X.
(2000). Selective Lymphoscintigraphy: A Necessary Adjunct to Dye-Directed Sentinel Node Biopsy for Breast Cancer?. Arch Surg
135: 1101-1105
[Abstract][Full Text]
Liptay, M. J., Masters, G. A., Winchester, D. J., Edelman, B. L., Garrido, B. J., Hirschtritt, T. R., Perlman, R. M., Fry, W. A.
(2000). Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Ann. Thorac. Surg.
70: 384-389
[Abstract][Full Text]
Giuliano, A. E., Haigh, P. I., Brennan, M. B., Hansen, N. M., Kelley, M. C., Ye, W., Glass, E. C., Turner, R. R.
(2000). Prospective Observational Study of Sentinel Lymphadenectomy Without Further Axillary Dissection in Patients With Sentinel Node-Negative Breast Cancer. JCO
18: 2553-2559
[Abstract][Full Text]
McMasters, K. M., Tuttle, T. M., Carlson, D. J., Brown, C. M., Noyes, R. D., Glaser, R. L., Vennekotter, D. J., Turk, P. S., Tate, P. S., Sardi, A., Cerrito, P. B., Edwards, M. J.
(2000). Sentinel Lymph Node Biopsy for Breast Cancer: A Suitable Alternative to Routine Axillary Dissection in Multi-Institutional Practice When Optimal Technique Is Used. JCO
18: 2560-2566
[Abstract][Full Text]
Burak, W. E. Jr, Owens, K. E., Tighe, M. B., Kemp, L., Dinges, S. A., Hitchcock, C. L., Olsen, J.
(2000). Vacuum-Assisted Stereotactic Breast Biopsy: Histologic Underestimation of Malignant Lesions. Arch Surg
135: 700-703
[Abstract][Full Text]
Harrington, K. J., Rowlinson-Busza, G., Syrigos, K. N., Uster, P. S., Vile, R. G., Stewart, J. S. W.
(2000). Pegylated Liposomes Have Potential as Vehicles for Intratumoral and Subcutaneous Drug Delivery. Clin. Cancer Res.
6: 2528-2537
[Abstract][Full Text]
Smith, B. L.
(2000). Approaches to Breast-Cancer Staging. NEJM
342: 580-581
[Full Text]
Lindblom, A., Liljegren, A.
(2000). Regular review: Tumour markers in malignancies. BMJ
320: 424-427
[Full Text]
Mandelblatt, J. S., Ganz, P. A., Kahn, K. L.
(1999). Proposed Agenda for the Measurement of Quality-of-Care Outcomes in Oncology Practice. JCO
17: 2614-2614
[Abstract][Full Text]
Pantel, K., Cote, R. J., Fodstad, O.
(1999). Detection and Clinical Importance of Micrometastatic Disease. JNCI J Natl Cancer Inst
91: 1113-1124
[Abstract][Full Text]
Reynolds, C., Mick, R., Donohue, J. H., Grant, C. S., Farley, D. R., Callans, L. S., Orel, S. G., Keeney, G. L., Lawton, T. J., Czerniecki, B. J.
(1999). Sentinel Lymph Node Biopsy With Metastasis: Can Axillary Dissection Be Avoided in Some Patients With Breast Cancer?. JCO
17: 1720-1720
[Abstract][Full Text]
Liberman, L., Cody, H. S. III, Hill, A. D. K., Rosen, P. P., Yeh, S. D. J., Akhurst, T., Morris, E. A., Abramson, A. F., Borgen, P. I., Dershaw, D. D.
(1999). Sentinel Lymph Node Biopsy after Percutaneous Diagnosis of Nonpalpable Breast Cancer. Radiology
211: 835-844
[Abstract][Full Text]
Thornton, H., Thomas, M., Beechey-Newman, N, Fentiman, I S, Young, A E, Dixon, J M.
(1999). Sentinel node biopsy in breast cancer. BMJ
318: 599-599
[Full Text]
Krag, D.
(1999). Current Status of Sentinel Lymph Node Surgery for Breast Cancer. JNCI J Natl Cancer Inst
91: 302-303
[Full Text]
Ganz, P. A.
(1999). The Quality of Life after Breast Cancer -- Solving the Problem of Lymphedema. NEJM
340: 383-385
[Full Text]
